Home > Gastroenterology > Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By
Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GI 2022
Trial
Phase 3, CheckMate 649, DELIVER
Nivolumab added to chemotherapy displayed ongoing increased efficacy over chemotherapy alone in treatment-naïve patients with advanced gastric cancer (GC), gastroesophageal junction cancer (GEJC), or oesophageal adenocarcinoma (OAC). The long-term follow-up data of the CheckMate 649 trial also did not show new safety issues for this combination regimen [1]. In addition, the observational DELIVER study revealed that host-related biomarkers in the gut microbiome could predict toxic events related to nivolumab therapy in patients with advanced GC [2]. The phase 3 CheckMate 649 trial (NCT02872116) previously showed that, after 12 months of follow-up, treatment with nivolumab plus chemotherapy was superior to chemotherapy alone in patients with advanced GC, GEJC, or OAC [3]. These results led to the approval of this regimen in the US and Europe. The CheckMate 649 trial ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on